Yantai Dongcheng Pharmaceutical Group Co., Ltd.
http://www.dcb-group.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Yantai Dongcheng Pharmaceutical Group Co., Ltd.
Chinese Radiopharma Developers Continue Fundraising Spree
Reflecting global interest in the field, Chinese radiopharma specialists PharmadaX Genesis, LNC Biotechnology and SmartNuclide have been on a winning streak to secure venture capital funding. Separately, Impact and Arnatar raised around $50m each in their latest venture capital- and private equity-backed fundraisings.
Radionuclide Therapy Developers Attract Investor Attention in March China Fundraising
China's Chengdu New Radiomedicine Technology and the radiotherapy CRDMO Mitro Biotech bagged a combined $94m in their respective new financing rounds during March. Meanwhile, Beijing Varnotech Biopharm secured $83m for its vaccine candidates for the prevention of herpes zoster and respiratory syncytial virus infections.
Company Information
- Industry
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Yantai Dongcheng Biochemicals Co., Ltd.
- Yantai LNC Biotechnology Singapore Pte. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice